Endocrine Activity of AVB, 2MR, BHA, and Their Mixtures

Ivana Klopcic1, Marija Sollner Dolenc1

  • 1Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia Aškerceva 7.

Insights

Three common cosmetic ingredients, 2-methylresorcinol, butylated hydroxyanisole, and avobenzone, show endocrine-disrupting activities, particularly affecting androgen and glucocorticoid receptors, and their mixtures can enhance these effects.

Area of Science:

  • Endocrinology
  • Toxicology
  • Cosmetic Science

Background:

  • Increasing personal care product use raises concerns about hormonal disruption.
  • Cosmetic ingredients bioaccumulate, necessitating analysis of endocrine activity on key receptors.
  • Simultaneous exposure to multiple endocrine-disrupting compounds is common.

Purpose of the Study:

  • To investigate the endocrine activity of 2-methylresorcinol (2MR), butylated hydroxyanisole (BHA), and avobenzone (AVB).
  • To assess the anti-androgen, anti-glucocorticoid, and anti-thyroid activities of these compounds and their mixtures.
  • To evaluate the influence of binary and ternary mixtures on endocrine receptor activity.

Main Methods:

  • Utilized the MDA-kb2 reporter cell line to assess anti-androgen and glucocorticoid activities.
  • Employed the GH3.TRE-Luc cell line to evaluate anti-thyroid and thyroid hormone-like activities.
  • Tested individual compounds and their mixtures (binary and ternary) at EC50 or IC50 concentrations.

Main Results:

  • 2MR and BHA demonstrated anti-androgen and glucocorticoid-like activities; AVB showed glucocorticoid activity.
  • Mixtures like 2MR + BHA and 2MR + BHA + AVB exhibited glucocorticoid-like activity.
  • The mixture 2MR + AVB showed anti-androgen activity, while no thyroid hormone-like activity was observed for any mixtures.

Conclusions:

  • Identified 2MR, BHA, and AVB as compounds with potential endocrine-disrupting effects.
  • Highlighted the importance of studying compound mixtures to fully assess human health risks.
  • Emphasized the need for comprehensive risk assessment considering combined effects of cosmetic ingredients.

Related Concept Videos

Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
4.0K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
4.2K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.1K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.8K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K